IVA
Inventiva S.A.
NASDAQ · Healthcare · Biotechnology · FR
$4.78
−1.24%Year over year
Reported trailing growth
- Revenue
- -64.6%
- EBITDA
- —
- EBIT
- -40.3%
- EPS
- -45.1%
- Free cash flow
- -52.5%
- Operating cash flow
- -53.4%
Forward estimates
Based on analyst estimates
- Revenue
- +140.4%
- EBITDA
- —
- EPS
- +39.2%
Three-year CAGR
- Revenue
- -28.3%
- EBITDA
- +23.0%
- EBIT
- -34.2%
- Net income
- -84.7%
- EPS
- +48.6%
- Free cash flow
- -17.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025